Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsDowngradesPrice Target
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.